North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Recent Updates - Updated items
All Formulary Amendments
Records 1 to 15 of 15
Details
UPD
sitematrix Changed from 0 to
16/06/2023 10:03:49
(dmcdermott )
UPD
FurtherInformation Changed from
Approved for use in previously treated Philadelphia-chromosome-negative acute lymphosblastic leukaemia in line with NICE and NHS England Commissioning Policy.
Approved for the treatment of acute lymphobl
16/06/2023 10:03:49
(dmcdermott )
UPD
Blinatumomab (Blincyto
®
) cd&tv notes
16/06/2023 10:03:49
(dmcdermott )
UPD
sitematrix Changed from 0 to
16/06/2023 10:01:43
(dmcdermott )
UPD
blackTriangle Changed from N to Y
16/06/2023 10:01:43
(dmcdermott )
UPD
Blinatumomab (Blincyto
®
) bt
16/06/2023 10:01:43
(dmcdermott )
UPD
sitematrix Changed from 0 to
27/07/2022 15:31:57
(LoweryM )
UPD
FurtherInformation Changed from
38.5 micrograms powder for concentrate and solution for solution for infusion
Approved for use in previously treated Philadelphia-chromosome-negative acute lymphosblastic leukaemia in line with NIC
27/07/2022 15:31:57
(LoweryM )
UPD
Blinatumomab (Blincyto
®
) strength removed
27/07/2022 15:31:57
(LoweryM )
LDL
Link Added : NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity : https://www.nice.org.uk/guidance/ta589
29/10/2019 15:37:50
(DavidS )
UPD
Blinatumomab (Blincyto
®
) updated with TA589
29/10/2019 15:37:14
(DavidS )
UPD
Published from Draft Mode
27/10/2017 15:16:43
(DavidS )
LDL
Link Added : NICE TA450 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia : https://www.nice.org.uk/guidance/ta450
26/10/2017 16:07:19
(DavidS )
UPD
Blinatumomab (Blincyto
®
) NICE TA450
26/10/2017 16:06:50
(DavidS )
UPD
Status Changed to | Hidden | Published
22/03/2017 15:10:45
(DavidS )